Form 4: Rocket Pharma Officer Sells Shares Under 10b5-1 Plan

John Militello, VP of Finance at Rocket Pharmaceuticals, sold 28,918 shares of common stock for approximately $114,500 under a pre-arranged trading plan.

Summary

• John Militello, Vice President of Finance, Treasurer, and Principal Accounting Officer of Rocket Pharmaceuticals, Inc. (RCKT), reported sales of common stock.
• The transactions occurred on October 14, 2025, and were made pursuant to a Rule 10b5-1(c) contract, instruction, or written plan.
• Militello sold a total of 28,918 shares across four separate transactions.
• The sales prices ranged from $3.96 to $3.975 per share.
• Following these transactions, Militello beneficially owns 67,006 shares of common stock, which includes Restricted Stock Units (RSUs) that convert to common stock on a one-for-one basis.

Sentiment

Score: 5

Explanation: The sale of shares by an officer is generally viewed neutrally to slightly negatively. However, the disclosure that it was executed under a 10b5-1 plan mitigates the negative sentiment, as it indicates a pre-scheduled transaction rather than a reaction to new, potentially negative, information.

Positives

• The sales were conducted under a Rule 10b5-1 plan, indicating pre-scheduled transactions rather than a reaction to immediate company news.

Negatives

• An officer selling a significant number of shares (28,918 shares) could be perceived negatively by investors, even if pre-planned.
• The total value of shares sold was approximately $114,500.

Future Outlook

NA

Management Comments

• John Militello holds the titles of Vice President of Finance, Treasurer, and Principal Accounting Officer.

Industry Context

Insider selling, even under a 10b5-1 plan, is a common occurrence in the biotech/pharma industry, often related to liquidity needs, diversification, or compensation vesting schedules. These transactions are typically viewed in the context of broader market and company performance.

Related Party Transactions

• The transactions involve an officer of Rocket Pharmaceuticals, Inc. selling company stock, which is a related party transaction in the context of insider trading rules.

Stakeholder Impact

• Shareholders may interpret the officer's sale of shares as a signal, though the 10b5-1 plan suggests it is not based on new, adverse information.

Key Dates

Recommendation

While an officer selling shares can sometimes be a negative signal, the disclosure that these sales were executed under a Rule 10b5-1 plan suggests they were pre-scheduled and not based on new, material non-public information. Therefore, this single Form 4 filing alone does not provide sufficient new information to warrant a change from a 'hold' recommendation, as it is a routine insider transaction.

Keywords

Rocket Pharmaceuticals, RCKT, John Militello, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Officer Transaction, Common Stock